Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07220876 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

A NA study of Open Angle Glaucoma (OAG), sponsored by Avisi Technologies.

Recruiting
Registry status
NA
Development phase
165
Enrollment target
12
Study locations

NCT07220876 is a NA study of Open Angle Glaucoma (OAG) that is actively recruiting participants, run by Avisi Technologies. The registered enrollment target is 165 participants, above the 35-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (371% higher). The trial reports 12 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07220876, a NA study of Open Angle Glaucoma (OAG), is actively recruiting participants, sponsored by Avisi Technologies.

RECRUITING
Registry status
NA
Development phase
165 participants
Enrollment target
12
Study locations

Study Summary

A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial

Conditions Studied

Interventions

  • DEVICE VisiPlate Glaucoma Implant

Study Locations (12)

Colorado

  • ICON Eye Care - Grand Junction
  • Mile High Eye Institute - Sheridan

Pennsylvania

  • Scheie Eye Institute - Philadelphia
  • Wills Eye Hospital - Philadelphia

Texas

  • Glaucoma Associates of Texas - Dallas
  • University of Texas Southwestern - Dallas

Other

  • Lynette Venter - Bloemfontein
  • Pretoria Eye Institute - Pretoria

Arizona

  • Arizona Advanced Eye Research - Glendale

California

  • Sacramento Eye Consultants - Sacramento

Ohio

  • Cleveland Clinic- Cole Eye Institute - Cleveland

Wisconsin

  • The Eye Centers of Racine & Kenosha - Kenosha

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2025-11-07
Est. Completion 2027-10
Phase NA

Sponsor

Avisi Technologies

1 total trials

What the Registry Record Tells You About NCT07220876

The ClinicalTrials.gov registry entry for NCT07220876 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (371% higher). The listed sponsor is Avisi Technologies, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 1 intervention - of which VisiPlate Glaucoma Implant is the first listed.

NCT07220876 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT07220876 about?

NCT07220876 is a clinical study titled "Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma". A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial

What is the current status of trial NCT07220876?

This trial is currently recruiting. It is a NA study. The enrollment target is 165 participants. The study started on 2025-11-07. Estimated completion is 2027-10.

What conditions does trial NCT07220876 study?

This clinical trial studies the following conditions: Open Angle Glaucoma (OAG).

What interventions are being tested in trial NCT07220876?

The interventions under investigation include: VisiPlate Glaucoma Implant (DEVICE).

Who is sponsoring clinical trial NCT07220876?

This trial is sponsored by Avisi Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07220876 being conducted?

This trial has 12 study locations across Arizona, California, Colorado, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Open Angle Glaucoma (OAG)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.